Now showing items 1-6 of 6

  • The evidence for switching dibenzazepines in people with epilepsy. 

    Watkins, L; O'Dwyer, M; Oak, K; Lawthom, C; Maguire, M; Thomas, R; Shankar, R (Denmark, 2020-08)
    The dibenzazepines particularly carbamazepine are associated with known adverse effects (AEs) and drug to drug interactions. Eslicarbazepine acetate (ESL) is structurally distinct from other members of the dibenzazepine ...
  • Intellectual Disability and Epilepsy 

    Shankar, R; Watkins, L; Brown, S (Springer, 2019-02-08)
    This book also acknowledges that the impact on the person and on their carers always needs to be taken into account, with treatment programs established with a multi-faceted team approach in mind.
  • Management of epilepsy in adults with intellectual disability 

    Shankar, R; Mogbeyiteren, E; Scheepers, M; Dolman, J; Watkins, L; Attavar, R; Carmody, E; Haut, F; Alexander, R; Devapriam, J; Roy, A; Kerr, M (Royal College of PsychiatristsUnited Kingdom, 2017-05-01)
    This long-awaited report offers an important step towards clarifying the role of the psychiatrist in ID in the management of epilepsy. The proposed tiered system of professional competency gives psychiatrists the option ...
  • Optimising medicines use in older adults with intellectual disability who have epilepsy: challenges and perspectives. 

    O'Dwyer, M; Watkins, L; McCallion, P; McCarron, M; Henman, M; Shankar, R (England, 2021)
  • Prescribing anti-epileptic drugs for people with epilepsy and intellectual disability 

    Shankar, R; Watkins, L; Alexander, R; Devapriam, J; Dolman, J; Hari, A; Laugharne, R; McLean, B; Ring, H; Sander, L; Scheepers, M; Tharian, R; Tittensor, P; Walker, M; Winterhalder, R (Royal College of PsychiatristsUnited Kingdom, 2017-10-01)
    This report addresses the extremely important area of epilepsy in the field of intellectual disability (ID), also known as learning disability. Epilepsy and ID are two conditions that carry stigma and can lead to social ...
  • Valproate MHRA Guidance: Limitations and Opportunities. 

    Watkins, L; Cock, H; Angus-Leppan, H; Morley, K; Wilcock, M; Shankar, R (Switzerland, 2019)
    Recent publication of the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom has strengthened the regulatory measures for valproate medicines. It highlights the importance of making women of ...

All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
@mire NV